Growing body of evidence
DiviTum has been studied widely in HR+ metastatic breast cancer, and also in other indications. The evidence demonstrates that measuring thymidine kinase activity levels with DiviTum provides important clinical data for the management of the disease.
To date, >10 publications support the application of DiviTum to potentially predicting and monitoring response to cell cycle regulating therapies: endocrine therapies, and CDK4/6 inhibitors.
The role of TK activity and the DiviTum®TKa test have been widely studied in breast cancer. Studies have shown the potential of the test as a monitoring tool and as a prognostic.